SS
IOVA icon

SBI Securities’s Iovance Biotherapeutics IOVA Stock Holding History

SBI Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Buy
12,355
+873
+8% +$3.32K ﹤0.01% 1148
2026
Q1 		$40.3K Sell
11,482
-86
-0.7% -$275 ﹤0.01% 1184
2025
Q4 		$31.6K Buy
11,568
+7,269
+169% +$16.8K ﹤0.01% 1268
2025
Q3 		$9.33K Buy
4,299
+1,649
+62% +$3.89K ﹤0.01% 1801
2025
Q2 		$4.56K Sell
2,650
-1,084
-29% -$2.7K ﹤0.01% 2028
2025
Q1 		$12.4K Sell
3,734
-1,196
-24% -$6.17K ﹤0.01% 1517
2024
Q4 		$36.5K Buy
+4,930
New +$45.7K ﹤0.01% 1081

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

SBI Securities's IOVA Position: Q2 2026 in Review

SBI Securities increased its Iovance Biotherapeutics (IOVA) stake by 7.6% in Q2 2026, buying an estimated $3.32K and bringing the position to 12,355 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

SBI Securities first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • SBI Securities held 12,355 shares of Iovance Biotherapeutics worth $51.4K as of Q2 2026.
  • SBI Securities bought 873 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.32K.
  • Iovance Biotherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1148 holding.
  • SBI Securities first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.